Thrivent Financial for Lutherans Has $1.62 Million Position in TransMedics Group, Inc. (NASDAQ:TMDX)

Thrivent Financial for Lutherans lessened its stake in TransMedics Group, Inc. (NASDAQ:TMDX) by 1.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 25,942 shares of the company’s stock after selling 254 shares during the period. Thrivent Financial for Lutherans owned about 0.08% of TransMedics Group worth $1,617,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Quarry LP lifted its position in shares of TransMedics Group by 557.1% in the 3rd quarter. Quarry LP now owns 368 shares of the company’s stock worth $58,000 after acquiring an additional 312 shares during the period. National Bank of Canada FI lifted its position in TransMedics Group by 174.7% in the third quarter. National Bank of Canada FI now owns 412 shares of the company’s stock worth $65,000 after purchasing an additional 262 shares during the period. Hager Investment Management Services LLC acquired a new stake in TransMedics Group during the fourth quarter worth $33,000. Sachetta LLC bought a new stake in TransMedics Group in the 4th quarter valued at $40,000. Finally, AlphaQuest LLC acquired a new position in shares of TransMedics Group in the 4th quarter valued at $52,000. 99.67% of the stock is owned by institutional investors and hedge funds.

TransMedics Group Price Performance

Shares of TMDX stock opened at $68.58 on Monday. TransMedics Group, Inc. has a 52 week low of $55.00 and a 52 week high of $177.37. The stock has a market capitalization of $2.31 billion, a PE ratio of 72.96 and a beta of 2.12. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20. The stock’s fifty day moving average is $69.11 and its 200-day moving average is $87.69.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on TMDX shares. JPMorgan Chase & Co. reiterated a “neutral” rating and set a $75.00 target price (down from $116.00) on shares of TransMedics Group in a research report on Tuesday, December 17th. Needham & Company LLC reaffirmed a “hold” rating on shares of TransMedics Group in a report on Wednesday, March 26th. Robert W. Baird dropped their target price on TransMedics Group from $150.00 to $120.00 and set an “outperform” rating for the company in a report on Wednesday, December 11th. Piper Sandler decreased their price target on TransMedics Group from $110.00 to $90.00 and set an “overweight” rating on the stock in a research note on Wednesday, December 11th. Finally, Canaccord Genuity Group reiterated a “buy” rating and set a $104.00 price objective on shares of TransMedics Group in a research note on Tuesday, March 11th. Three research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $122.70.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.